HOME >> BIOLOGY >> NEWS
Work begins on powering a sustainable future for the UK

Work is getting underway to take the UK into a significantly more sustainable way of meeting its energy needs for the future.

Four Consortia, set up earlier this year under the SUPERGEN initiative, will now start working at ways of improving the UK's renewable power generation and supply systems. These collaborations are covering the areas of Marine Energy, Networks & Power Control, Hydrogen Energy & Storage and Biomass & Biofuels.

SUPERGEN is managed by the Engineering and Physical Sciences Research Council.

The inauguration keynote address will be given by Stephen Timms MP, Minister for Energy, e-Commerce and Postal Services.

The SUPERGEN initiative was launched in September 2001. It is investing more than 25M over five years in sustainable power generation. These four virtual centres are the first to be funded through this initiative and each will run for four years.

This research cuts across many disciplines incorporating political, social, environmental and economic factors covering climate change, fossil fuel extraction rates, emissions control and increasing public awareness of environmental concerns.

The multidisciplinary nature of this research is reflected in the fact that the EPSRC is managing the SUPERGEN initiative working with the Biotechnology and Biological Sciences Research Council (BBSRC), the Economic and Social Research Council (ESRC) and the Natural Environment Research Council (NERC).

Each Consortia brings together leading researchers working alongside industry. A key element of the SUPERGEN philosophy is that interaction with industry will lead to "real world" problems being addressed.

It will also be announced at the event that the Carbon Vision Partnership will be investing 4 6 M over the next 3 4 years in R&D focused on the generation and supply of low carbon power. This investment will be channelled through SUPERGEN, and will increase the R&D investment in this key
'"/>

Contact: Jane Reck
jane.reck@epsrc.ac.uk
01-793-444-312
Engineering and Physical Sciences Research Council
11-Nov-2003


Page: 1 2 3 4

Related biology news :

1. New hydrothermal vents discovered as South Pacific Odyssey research begins
2. DCI donor services begins distribution of tissue implants
3. Landmark, pivotal Phase IIb/III trial of biotoxin for cancer pain begins
4. As autumn approaches, this chickadees brain begins to expand
5. New study begins to unravel fate of toxic pollutants harbored in Arctic waters
6. UCSF begins distributing the first of its two embryonic stem cell lines
7. Acorda Therapeutics begins Phase 3 trials of Fampridine-SR for chronic spinal cord injury
8. Nabi Biopharmaceuticals begins human testing of novel vaccine to fight nicotine addiction
9. The pathway to anxiety begins early in life
10. DOE begins international effort to sequence tree genome
11. Montana State University begins major trout and salmonid book collection

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Work begins powering sustainable future for the

(Date:7/8/2015)... DIEGO , July 8, 2015  Trovagene, ... cell-free molecular diagnostics, today announced the launch of ... the Company,s Precision Cancer Monitoring℠ (PCM) technology for ... receiving one or a combination of the novel ... Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient study ...
(Date:7/7/2015)... -- Research and Markets ( ... "Capacitive Fingerprint Sensors Patent Landscape" report ... fingerprint sensing technology is the most reliable and ... developed. This patent landscape focuses on fingerprint sensors ... of capacitive fingerprint sensors is closely linked to ...
(Date:7/7/2015)... 7, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... mobile commerce market announces a revised version of one of its ... will air on CNBC in New York , ... and San Francisco metro areas.    ... Wocket,s ability to replace all the cards in your wallet and ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
(Date:7/29/2015)... , ... July 29, 2015 , ... The third Medical ... combination products , in particular, drug/device combinations. The current system received a score ... Initiative for Patient Centered Innovation (iPCI) of Fairleigh Dickinson University’s ( FDU ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... it has selected an optimized Erk inhibitor molecule ... the development of a new class of potential ... represents a prime target for therapeutic intervention in ... and survival benefits for B-Raf and Mek inhibitors. ...
(Date:7/29/2015)... ... July 29, 2015 , ... CSSi ... Silicon Valley-based CRO specializing in Clinical Trial Management. CSSi LifeSciences is specialized in ... core expertise of PRC Clinical is focused on Clinical Trial Management, Clinical Site ...
(Date:7/29/2015)... TX (PRWEB) , ... July 29, 2015 , ... Costello ... new levee system to protect the Orange County, Texas area from future storm ... multi-firm design team in determining several potential levee alignment alternatives for providing protection, Costello ...
Breaking Biology Technology:Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3Preventing Storm Surge Flooding in Houston 2
Cached News: